Trevi Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
10-K: Trevi Therapeutics Reports Positive Phase 2a Data and Outlines Future Plans in Annual 10-K Filing
Trevi Therapeutics' 10-K filing highlights positive clinical trial results for Haduvio and outlines the company's strategy for future development and commercialization.
NASDAQ
Trevi Therapeutics' 10-K filing details its capital structure, stock information, and regulatory environment, emphasizing its focus on developing Haduvio for chronic cough and pruritus.